PL2785711T3 - Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona - Google Patents
Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsonaInfo
- Publication number
- PL2785711T3 PL2785711T3 PL12794308T PL12794308T PL2785711T3 PL 2785711 T3 PL2785711 T3 PL 2785711T3 PL 12794308 T PL12794308 T PL 12794308T PL 12794308 T PL12794308 T PL 12794308T PL 2785711 T3 PL2785711 T3 PL 2785711T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrid
- parkinson
- phenyl
- disease
- treatment
- Prior art date
Links
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564755P | 2011-11-29 | 2011-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2785711T3 true PL2785711T3 (pl) | 2017-01-31 |
Family
ID=47263348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12794308T PL2785711T3 (pl) | 2011-11-29 | 2012-11-28 | Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8791130B2 (pl) |
| EP (2) | EP3121174A1 (pl) |
| JP (1) | JP6180426B2 (pl) |
| KR (1) | KR102025451B1 (pl) |
| CN (2) | CN106243090A (pl) |
| BR (1) | BR112014009717B1 (pl) |
| CA (1) | CA2850705C (pl) |
| CY (1) | CY1118135T1 (pl) |
| DK (1) | DK2785711T3 (pl) |
| ES (1) | ES2592802T3 (pl) |
| HR (1) | HRP20161396T1 (pl) |
| HU (1) | HUE030694T2 (pl) |
| LT (1) | LT2785711T (pl) |
| MX (1) | MX348920B (pl) |
| PL (1) | PL2785711T3 (pl) |
| PT (1) | PT2785711T (pl) |
| RS (1) | RS55370B1 (pl) |
| RU (1) | RU2647849C2 (pl) |
| SI (1) | SI2785711T1 (pl) |
| WO (1) | WO2013079495A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2638031T1 (en) * | 2010-11-10 | 2018-02-28 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
| CN103958498B (zh) * | 2011-11-29 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| US20140228384A1 (en) * | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
| AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| BR112014027117B1 (pt) * | 2012-05-03 | 2022-09-06 | Genentech, Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição |
| WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EP3733184B1 (en) | 2013-03-14 | 2023-08-30 | Icahn School of Medicine at Mount Sinai | Pyrimidine compounds for use in the treatment of cancer |
| WO2015069752A1 (en) * | 2013-11-05 | 2015-05-14 | The Regents Of The University Of California | Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using |
| WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
| US9975873B2 (en) * | 2014-10-08 | 2018-05-22 | Ucb Biopharma Sprl | Isoindoline derivatives |
| EP3778605A3 (en) * | 2015-02-13 | 2021-03-10 | Dana Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| IL299415B2 (en) | 2016-06-16 | 2025-09-01 | Denali Therapeutics Inc | Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders |
| AR113893A1 (es) | 2017-11-21 | 2020-06-24 | Denali Therapeutics Inc | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
| CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| EP3966206B1 (en) | 2019-05-10 | 2023-08-09 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| JP7626722B2 (ja) * | 2019-06-17 | 2025-02-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
| KR102252879B1 (ko) * | 2019-11-15 | 2021-05-17 | 성균관대학교산학협력단 | 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트 |
| WO2021143729A1 (zh) * | 2020-01-15 | 2021-07-22 | 中国科学院上海药物研究所 | 多靶点抑制作用化合物、组合物、功能分子及其应用 |
| KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| AU2021243887A1 (en) | 2020-03-23 | 2022-11-03 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
| EP4232040A1 (en) | 2020-10-20 | 2023-08-30 | F. Hoffmann-La Roche AG | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
| CN120826397A (zh) | 2022-11-03 | 2025-10-21 | 戴纳立制药公司 | 嘧啶三唑化合物的固体及共晶体形式 |
| EP4622972A1 (en) | 2022-11-22 | 2025-10-01 | Denali Therapeutics Inc. | Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002312933B2 (en) * | 2001-05-29 | 2007-12-06 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
| DK1438053T3 (da) * | 2001-10-17 | 2008-12-08 | Boehringer Ingelheim Pharma | Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling |
| KR20050084027A (ko) * | 2002-11-28 | 2005-08-26 | 쉐링 악티엔게젤샤프트 | Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도 |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US20080131937A1 (en) | 2006-06-22 | 2008-06-05 | Applera Corporation | Conversion of Target Specific Amplification to Universal Sequencing |
| AU2009216851B2 (en) * | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| SG179120A1 (en) | 2009-09-29 | 2012-05-30 | Glaxo Group Ltd | Novel compounds |
| US8354420B2 (en) * | 2010-06-04 | 2013-01-15 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 inhibitors |
| SI2638031T1 (en) * | 2010-11-10 | 2018-02-28 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
| CA2852609C (en) * | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| CN103958498B (zh) * | 2011-11-29 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
-
2012
- 2012-11-28 LT LTEP12794308.2T patent/LT2785711T/lt unknown
- 2012-11-28 HR HRP20161396TT patent/HRP20161396T1/hr unknown
- 2012-11-28 US US13/687,421 patent/US8791130B2/en active Active
- 2012-11-28 KR KR1020147017591A patent/KR102025451B1/ko active Active
- 2012-11-28 MX MX2014006210A patent/MX348920B/es active IP Right Grant
- 2012-11-28 JP JP2014543867A patent/JP6180426B2/ja active Active
- 2012-11-28 PT PT127943082T patent/PT2785711T/pt unknown
- 2012-11-28 CN CN201610618072.1A patent/CN106243090A/zh active Pending
- 2012-11-28 EP EP16179983.8A patent/EP3121174A1/en not_active Withdrawn
- 2012-11-28 BR BR112014009717-8A patent/BR112014009717B1/pt active IP Right Grant
- 2012-11-28 EP EP12794308.2A patent/EP2785711B1/en active Active
- 2012-11-28 HU HUE12794308A patent/HUE030694T2/en unknown
- 2012-11-28 PL PL12794308T patent/PL2785711T3/pl unknown
- 2012-11-28 RU RU2014124639A patent/RU2647849C2/ru active
- 2012-11-28 WO PCT/EP2012/073768 patent/WO2013079495A1/en not_active Ceased
- 2012-11-28 ES ES12794308.2T patent/ES2592802T3/es active Active
- 2012-11-28 CA CA2850705A patent/CA2850705C/en active Active
- 2012-11-28 RS RS20160925A patent/RS55370B1/sr unknown
- 2012-11-28 DK DK12794308.2T patent/DK2785711T3/en active
- 2012-11-28 CN CN201280058780.4A patent/CN103958503B/zh active Active
- 2012-11-28 SI SI201230747A patent/SI2785711T1/sl unknown
-
2016
- 2016-10-05 CY CY20161100995T patent/CY1118135T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6180426B2 (ja) | 2017-08-16 |
| DK2785711T3 (en) | 2016-09-05 |
| KR20140094649A (ko) | 2014-07-30 |
| CA2850705C (en) | 2020-03-10 |
| MX2014006210A (es) | 2014-08-08 |
| US20130158057A1 (en) | 2013-06-20 |
| RU2014124639A (ru) | 2016-01-27 |
| CY1118135T1 (el) | 2017-06-28 |
| RS55370B1 (sr) | 2017-03-31 |
| BR112014009717B1 (pt) | 2022-06-14 |
| WO2013079495A1 (en) | 2013-06-06 |
| CA2850705A1 (en) | 2013-06-06 |
| RU2647849C2 (ru) | 2018-03-21 |
| SI2785711T1 (sl) | 2016-12-30 |
| CN103958503B (zh) | 2016-09-28 |
| LT2785711T (lt) | 2016-10-25 |
| BR112014009717A2 (pt) | 2017-04-18 |
| US8791130B2 (en) | 2014-07-29 |
| EP2785711A1 (en) | 2014-10-08 |
| EP2785711B1 (en) | 2016-08-03 |
| HRP20161396T1 (hr) | 2016-12-02 |
| CN106243090A (zh) | 2016-12-21 |
| CN103958503A (zh) | 2014-07-30 |
| MX348920B (es) | 2017-07-04 |
| ES2592802T3 (es) | 2016-12-01 |
| JP2014533737A (ja) | 2014-12-15 |
| BR112014009717A8 (pt) | 2018-01-16 |
| KR102025451B1 (ko) | 2019-09-25 |
| PT2785711T (pt) | 2016-09-30 |
| HUE030694T2 (en) | 2017-06-28 |
| EP3121174A1 (en) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2785711T1 (sl) | 2-(fenil ali pirid-3-il)aminopirimidinski derivati kot modulatorji kinaze LRRK2 za zdravljenje Parkinsonove bolezni | |
| IL272622A (en) | Use of proton tyrosine kinase inhibitors | |
| IL236495A0 (en) | Heteroaromatic compounds as proton tyrosine kinase inhibitors | |
| ZA201000106B (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| ZA201000087B (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| MX2014012945A (es) | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). | |
| SG2014009260A (en) | Aminopyrimidine derivatives for use as modulators of kinase activity | |
| ZA201400012B (en) | Inhibitors of bruton's tyrosine kinase | |
| MX349556B (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| ZA201308397B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201209381B (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
| ZA201400739B (en) | Inhibitors of bruton's tyrosine kinase | |
| IL231591A0 (en) | Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| EP2925740A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
| AP2015008381A0 (en) | Bruton's tyrosine kinase inhibitors | |
| MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
| WO2011163452A9 (en) | Treating surface of the eye disorders | |
| EP2699569A4 (en) | AMINOPYRIMIDINKINASEHEMMER | |
| AP2013006987A0 (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| PL2483266T3 (pl) | Związki do leczenia dyslipidemii i chorób pokrewnych | |
| IN2012DN06061A (pl) | ||
| CA2863110A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators | |
| HK1197361A (en) | Inhibitors of bruton's tyrosine kinase | |
| HK1193975A (en) | Cystamine analogues for the treatment of parkinson's disease | |
| HK1143138A (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |